Kurt Tong is managing partner at global strategic advisory firm The Asia Group. He previously served as deputy chief of mission at the U.S. Embassy in Tokyo and in other senior diplomatic roles.
A number of innovative pharmaceutical companies seeking to bring specialized medicines and rare treatments to Japan are facing a Catch-22 situation, caught between contradictory policies created to respond to competing goals that coexist within Tokyo's bureaucracy.
